Patient-level Characteristics | Total (N = 3,535) | Filgrastim (N = 163) | Pegfilgrastim (N = 3,372) | P-value |
---|---|---|---|---|
Age, mean (SD) | 55.2 (10.8) | 57.5 (12.6) | 55.1 (10.7) | 0.018 |
Female, n (%) | 2,788 (78.9) | 119 (73.0) | 2,669 (79.2) | 0.060 |
Geographic region, n (%) | ||||
Northeast | 248 (7.0) | 26 (16.0) | 222 (6.6) | <0.001 |
Midwest | 970 (27.4) | 38 (23.3) | 932 (27.6) | 0.227 |
South | 1,778 (50.3) | 79 (48.5) | 1,699 (50.4) | 0.632 |
West | 539 (15.3) | 20 (12.3) | 519 (15.4) | 0.279 |
Tumor type, n (%) | ||||
Breast cancer | 2,054(58.1) | 84 (51.5) | 1,970 (58.4) | 0.082 |
Colorectal cancer | 46 (1.3) | 7 (4.3) | 39 (1.2) | <0.001 |
Lung cancer | 634 (17.9) | 30 (18.4) | 604 (17.9) | 0.873 |
Non-Hodgkin’s lymphoma | 594 (16.8) | 33 (20.3) | 561 (16.6) | 0.229 |
Ovarian cancer | 207 (5.9) | 9 (5.5) | 198 (5.9) | 0.852 |
Baseline Quan-Charlson comorbidity score, mean (SD)*† | 4.5 (2.4) | 4.4 (2.5) | 4.5 (2.4) | 0.520 |
Score of 2, n (%) | 1,131 (32.0) | 57 (35.0) | 1,074 (31.9) | 0.404 |
Score of 3–6, n (%) | 1,590 (45.0) | 61 (37.4) | 1,529 (45.3) | 0.047 |
Score of ≥ 7, n (%) | 805 (22.8) | 44 (27.0) | 761 (22.6) | 0.188 |
History of anemia‡§ | 3,858 (32.0) | 135 (36.2) | 3,723 (31.9) | 0.078 |
Count of myelosuppressive chemotherapy agents, mean (SD) for cycles§** | 2.13 (0.6) | 1.96 (0.6) | 2.14 (0.6) | <0.001 |
Use duration, mean (SD)†† | - | 4.8 (3.3) | ‡‡ | - |
1 day, % | - | 19.9 | - | - |
2 days, % | - | 9.9 | - | - |
3 days, % | - | 14.0 | - | - |
4–6days, % | - | 23.9 | - | - |
≥ 7 days, % | - | 32.3 | - | - |